Currently Viewing:
Newsroom
Currently Reading
Bone Marrow Environment in Patients With RA May Promote Inflammation
December 12, 2017 – Kelly Davio
Researchers Say Medicare Advantage Plans Need Better Incentives to Meet Future Demand
December 12, 2017 – Allison Inserro
University, Genetics Firm Find Link Between ADHD, Delay Discounting
December 12, 2017 – Allison Inserro
Welltok Identifies Who's at Risk for Getting and Spreading the Flu
December 12, 2017 – Jaime Rosenberg
What We're Reading: Medical Device Approval; Medical Laboratories Sue Government; ACA Sign-Up Deadline
December 12, 2017 – AJMC Staff
What's the Magic Payment Mix for Medicare Primary Care Providers?
December 11, 2017 – Allison Inserro
Racial Disparities Prevalent in Survival of Patients With Ovarian, Colon, and Breast Cancer
December 11, 2017 – Jaime Rosenberg
Sanofi's Insulin Lispro Follow-On, Admelog, Wins FDA Approval
December 11, 2017 – Mary Caffrey
The Past, Present, and Future of HIV Funding
December 11, 2017 – Jaime Rosenberg

FDA Rejects Abuse-Deterrent Opioid, Seeks Additional Information

Laura Joszt
The FDA has rejected an abuse-deterrent opioid citing the need for further evidence. Rexista, an Oxycodone Hydrochloride Extended-Release tablet (Oxycodone ER), was developed by Intellipharmaceutics International Inc as an abuse- and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for pain relief.
The FDA has rejected an abuse-deterrent opioid citing the need for further evidence. Rexista, an Oxycodone Hydrochloride Extended-Release tablet (Oxycodone ER), was developed by Intellipharmaceutics International Inc as an abuse- and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for pain relief.

The FDA sent a Complete Response Letter to the company requesting more information, as well as that Intellipharmaceutics complete more studies to assess the abuse-deterrent properties of Oxycodone ER by the oral and nasal routes. The agency is also looking for more information about the blue dye that is intended to deter abuse.

According to Isa Odidi, PhD, MBA, CEO of Intellipharmaceutics, the letter from the FDA was encouraging since it clarifies the path going forward.

"We will continue to work closely with the FDA to provide them with the additional information they requested, including data supporting the label claims related to Oxycodone ER's abuse-deterrent properties,” Odidi said in a statement. “We believe our Oxycodone ER product can play an important preventative role in the midst of a serious opioid abuse crisis particularly impacting North America. The Company will be providing regular updates as we execute on our Oxycodone ER NDA resubmission plan."

The company has 1 year to respond to the letter from the FDA, but can request additional time. In addition, the FDA has asked that Intellipharmaceutics submit an alternative proprietary name for the drug.

In June, the FDA Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 22-1 against approving Intellipharmaceutics’ New Drug Application for Rexista. They also voted 19-4 that Rexista hadn’t been proven to deter abuse by intravenous methods.

Rexista is supposed to be difficult to abuse because when it is crushed or pulverized, the drug coagulates, which makes it difficult to inject or snort. The drug has a blue dye that is emitted once the tablet is tampered with—the expectation was that the blue dye may act as a deterrent because of stigma and serve as an early warning to flag potential misuse or abuse.

At the 30th US Psychiatric and Mental Health Congress Thomas Kosten, MD, a psychiatrist with Baylor College of Medicine, explained that there is evidence that tamper-resistant and abuse-resistant formulations of opioids decrease the abuse of that specific drug, but that payers aren’t as willing to cover these formulations because they cost substantially more.



 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!